Using oncolytic viruses to improve treatment and imaging for pancreatic cancer
Official title: Advancing Systematic Delivery of Oncolytic Adenovirus for Pancreatic Cancer
Funded at University of Minnesota · NIH-10874733 · Data updated 2026-11-12
This study is exploring a new way to treat pancreatic cancer using special viruses that can attack cancer cells and help doctors see how well the treatment is working, and it's designed to help patients by making therapies more effective and improving how their progress is tracked.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $478,754 |
| NIH project number | 5R01CA276179-02 |
| Project ID | NIH-10874733 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who are seeking innovative treatment options.
✕Less likely to help
Patients with other types of cancer or those who do not have pancreatic ductal adenocarcinoma may not benefit from this research.
What this research studies
This research focuses on developing a new treatment approach for pancreatic ductal adenocarcinoma (PDAC) using oncolytic adenoviruses that can both target cancer cells and enhance imaging techniques. The project aims to create a swine model that can better mimic human responses to these therapies, as current animal models are inadequate. By using a specific type of adenovirus that can induce uptake of radioactive iodine, the research seeks to improve both the diagnosis and treatment of this challenging cancer. Patients may benefit from more effective therapies and better monitoring of their disease progression.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options and improved diagnostic capabilities for patients with pancreatic cancer.
How similar studies have gone: While the use of oncolytic viruses in cancer treatment is a growing field, this specific approach using a swine model for pancreatic cancer is relatively novel and has not been extensively tested.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Davydova, Julia — University of Minnesota
- Study coordinator: Davydova, Julia
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.